Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune ...

A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.

“The FDA’s decision to grant Fast Track designation for TEV-53408, an investigational anti-IL-15 antibody therapy, reflects the promising nature of the treatment and the urgent unmet need of people ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

A man’s acquired hemophilia coincided with a rare liver disease, a connection that had not been reported before, per a case ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory ...

The antibody PLT012 targets the fat transporter CD36 to restore immune responses in tumors, offering a new and promising ...